Clinical Predictors of Survival in Cancer Patients With Metastatic Solid Tumors

NCT00322634 | Completed DMC

• 1 other identifier: INST 0535C
• Study Type: observational
• Target: 25
• Locations: 1 country
• Sites: 5

Brief Summary

The use of performance status and LDH in combination can predict patient survival more accurately than physician clinical impression or the patients' own feelings about their survival

Conditions

Cancer

Outcome Measures

Primary Outcomes (1)

• Disease Progression

  2 years

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients with metastatic solid tumors.

You may qualify if:

• All patients must be at least 18 years of age
• All patients must have documented incurable metastatic cancer
• All patients must have exhausted any treatments which are known to prolong survival in their disease, or have elected not to receive further life-prolonging therapy. Specifically, patients with the following are eligible:
• Non-small cell lung cancer patients after third systemic therapy
• Small cell lung cancer patients after second systemic therapy
• Breast cancer patients after third cytotoxic therapy (does not include hormonal therapy)
• Colorectal cancer patients after second systemic therapy
• Hormone refractory prostate cancer patients after first cytotoxic therapy
• Cancer of unknown primary
• Pancreatic cancer patients after first systemic therapy
• The use of systemic (chemotherapy, immunotherapy) or local treatments (XRT) for palliation of symptoms is allowed
• Patients with a history of previous cancers are allowed
• Patients with a history of other significant disease (e.g. heart disease, COPD, etc.) are allowed
• All patients must sign informed consent

You may not qualify if:

• Patients with acute or chronic leukemia, Hodgkin's disease, or non-Hodgkins lymphoma are excluded
• Patients who do not sign informed consent are excluded

Sponsors & Collaborators

• New Mexico Cancer Research Alliance: lead

Study Sites (5)

Hematology Oncology Associates

Albuquerque, New Mexico, 87102-3661, United States

Location

Radiation Oncology Associates

Albuquerque, New Mexico, 87111, United States

Location

University of New Mexico

Albuquerque, New Mexico, 87131, United States

Location

New Mexico Cancer Care Associates

Santa Fe, New Mexico, 87505, United States

Location

St. Vincent Regional Medical Center

Santa Fe, New Mexico, 87505, United States

Location

MeSH Terms

Conditions

Neoplasms

Study Officials

• Malcolm Purdy, MD

  Hematology & Oncology Associates

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 5, 2006
• First Posted: May 8, 2006
• Study Start: February 1, 2006
• Primary Completion: July 1, 2011
• Study Completion: July 1, 2011
• Last Updated: September 19, 2012

Record last verified: 2011-08

Locations

US (5)